NEW YORK, December 23, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Biogen Idec Inc. (NASDAQ: BIIB), Express Scripts Inc. (NASDAQ: ESRX), GlaxoSmithKline plc (NYSE: GSK), Actavis plc (NYSE: ACT), and Aetna Inc. (NYSE: AET). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Biogen Idec Inc. Research Report
On December 17, 2013, Biogen Idec Inc. (Biogen) and Samsung Bioepis jointly announced an agreement to commercialize anti-TNF biosimilar product candidates in Europe, that include biosimilars for commonly used therapies to help treat conditions like rheumatoid arthritis and Crohn's disease. Tony Kingsley, Executive Vice President of Global Commercial Operations for Biogen, commented, "This is a unique opportunity for us to leverage our experience in developing and manufacturing high-quality biologics in therapeutic areas where we are deeply focused, and provide medicines to patients where there is a significant societal need." Kingsley added, "As a company that aims to make a difference in the lives of patients with serious diseases, we are excited by the potential to offer additional highly effective therapies in critical areas where there is growing demand." The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Express Scripts Inc. Research Report
On December 18, 2013, Express Scripts Inc.'s (Express Scripts) stock increased 1.63%, ending the day's session at $67.98. Over the previous three trading sessions, shares of Express Scripts increased 2.04%, compared to the Nasdaq Composite Index, which increased 1.73% during the same period. The Full Research Report on Express Scripts Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
GlaxoSmithKline plc Research Report
On December 18, 2013, GlaxoSmithKline plc (GSK) and Theravance, Inc. (Theravance) jointly announced that the US Food and Drug Administration (FDA) has approved ANORO ELLIPTA as a combination anticholinergic/long-acting beta2-adrenergic agonist (LABA) indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Darrell Baker, Senior Vice President and Head, GSK Global Respiratory Franchise, said, "We believe Anoro Ellipta will be an important treatment option for appropriate patients with COPD. It is the first combination product approved in the US that delivers two once-daily bronchodilators in a single inhaler. This approval is a significant achievement for GSK." Rick E Winningham, CEO of Theravance, added, "This is a significant milestone for Theravance and GSK and is testament to our ongoing partnership and shared commitment to the development of respiratory medicines." The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Actavis plc Research Report
On December 11, 2013, Actavis plc (Actavis) reported that its subsidiary, Warner Chilcott Company, LLC (Warner Chilcott), has signed into an agreement in principle with Zydus Pharmaceuticals USA Inc. (Zydus) and Cadila Healthcare Limited (Cadila) to settle all outstanding patent litigation related to Zydus' generic version of Asacol HD (mesalamine) delayed-release tablets. The Company said that in accordance with the terms of the agreement in principle, Warner Chilcott will grant Zydus a royalty-bearing license to market its generic Asacol HD beginning on November 15, 2015 or earlier under certain circumstances, after the receipt of final approval by Zydus from the US Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for generic Asacol HD. Additionally, Actavis stated that if Zydus is not granted FDA approval for its generic Asacol HD by July 1, 2016, Zydus will be allowed to launch an authorized generic version of Actavis' product beginning on July 1, 2016. The Full Research Report on Actavis plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Aetna Inc. Research Report
On December 12, 2013, Aetna Inc. (Aetna) announced a new strategy to help employers and their employees achieve the full value of a consumer directed health plan (CDHP). Aetna reported that its strategy, CDHP Accelerator unites CDHPs with voluntary products, and gives greater financial protection after the member reaches certain limits on their high-deductible health plan. Jeff Brown, Head of Aetna Voluntary Plans, said, "We have seen that greater CDHP participation leads to greater employee engagement, which can lead to better health outcomes as well as cost savings for both employers and employees." Brown added, "With the right combination of voluntary benefits we can make the transition easier for consumers." The Full Research Report on Aetna Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner